MacroGenics (MGNX) Projected to Post Earnings on Wednesday

Posted by Geri Gentry on Nov 4th, 2026

MacroGenics (NASDAQ:MGNX – Get Free Report) will likely be posting its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect MacroGenics to announce earnings of ($0.3151) per share and revenue of $39.18 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

MacroGenics (NASDAQ:MGNX – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.39. MacroGenics had a negative return on equity of 109.26% and a negative net margin of 8.70%. The company had revenue of $32.83 million during the quarter, compared to the consensus estimate of $59.14 million. On average, analysts expect MacroGenics to post ($1.14) EPS for the current fiscal year and ($1.25) EPS for the next fiscal year.

MacroGenics Price Performance

Shares of MacroGenics stock traded up $0.06 during trading hours on Wednesday, hitting $2.39. The company’s stock had a trading volume of 25,446 shares, compared to its average volume of 956,373. The company has a market capitalization of $152.24 million, a PE ratio of -10.85 and a beta of 1.33. The stock has a 50 day moving average of $3.62 and a 200 day moving average of $3.41. MacroGenics has a 12 month low of $1.29 and a 12 month high of $5.08.

Analyst Ratings Changes

Several equities analysts recently issued reports on MGNX shares. B. Riley Financial boosted their price objective on MacroGenics from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, August 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of MacroGenics in a research note on Tuesday. Finally, Citigroup started coverage on shares of MacroGenics in a report on Friday, October 23rd. They set a “positive” rating on the stock. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MacroGenics has an average rating of “Hold” and an average target price of $8.50.

View Our Latest Stock Report on MacroGenics

Insiders Place Their Bets

In related news, VP Jeffrey Peters sold 31,105 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $4.15, for a total transaction of $129,085.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.60% of the stock is currently owned by company insiders.

MacroGenics Company Profile

(Get Free Report)

MacroGenics, Inc is a biopharmaceutical company focused on developing antibody-based therapies for cancer and immune-mediated diseases. Headquartered in Rockville, Maryland, the company uses its proprietary DART platform and other antibody technologies to create treatments designed to modulate immune responses and target disease-associated cells.

MacroGenics’ portfolio includes MARGENZA (margetuximab-cmkb), an antibody therapy approved in the United States for certain patients with HER2-positive metastatic breast cancer.